Company news

NRX Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NRx Pharmaceuticals (NASDAQ: NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing

June 27, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

May 6, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

May 5, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

April 29, 2024

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

April 17, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

April 16, 2024

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

April 16, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

April 14, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

April 7, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 31, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

March 27, 2024

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

March 27, 2024

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024

March 20, 2024

NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders

March 20, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders

March 17, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

March 10, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

March 3, 2024

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share

February 29, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)

February 11, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

February 4, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

January 21, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination

January 16, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

January 15, 2024

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

December 26, 2023

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression

December 18, 2023

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

December 17, 2023

NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders

December 12, 2023

NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 12, 2023

NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023

November 6, 2023

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

November 5, 2023

NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression

October 30, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

October 25, 2023

NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference

October 11, 2023

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

October 1, 2023

NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression

September 14, 2023

NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support

September 13, 2023

NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens

September 5, 2023

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

August 29, 2023

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share

August 28, 2023

NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 13, 2023

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain

August 6, 2023

NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering

June 5, 2023

NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023

NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call

May 9, 2023

NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

April 26, 2023

NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update

March 29, 2023

NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression

March 26, 2023

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

March 16, 2023

NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering

March 8, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.